Alexander M Rossor1, Pedro J Tomaselli, Mary M Reilly. 1. MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London WC1N 3BG, United Kingdom.
Abstract
PURPOSE OF REVIEW: Charcot-Marie-Tooth disease (CMT) is one of the commonest inherited neuromuscular diseases with a population prevalence of 1 in 2500. This review will cover recent advances in the genetics and pathomechanisms of CMT and how these are leading to the development of rational therapies. RECENT FINDINGS: Pathomechanistic and therapeutic target advances in CMT include the identification of the ErbB receptor signalling pathway as a therapeutic target in CMT1A and pharmacological modification of the unfolded protein response in CMT1B. In CMT2D, due to mutations in glycyl-tRNA synthetase, vascular endothelial growth factor-mediated stimulation of the Nrp1 receptor has been identified as a therapeutic target. Preclinical advances have been accompanied by the publication of large natural history cohorts and the identification of a sensitive biomarker of disease (muscle MRI) that is able to detect disease progression in CMT1A over 1 year. SUMMARY: Advances in next-generation sequencing technology, cell biology and animal models of CMT are paving the way for rational treatments. The combination of robust natural history data and the identification of sensitive biomarkers mean that we are now entering an exciting therapeutic era in the field of the genetic neuropathies.
PURPOSE OF REVIEW: Charcot-Marie-Tooth disease (CMT) is one of the commonest inherited neuromuscular diseases with a population prevalence of 1 in 2500. This review will cover recent advances in the genetics and pathomechanisms of CMT and how these are leading to the development of rational therapies. RECENT FINDINGS: Pathomechanistic and therapeutic target advances in CMT include the identification of the ErbB receptor signalling pathway as a therapeutic target in CMT1A and pharmacological modification of the unfolded protein response in CMT1B. In CMT2D, due to mutations in glycyl-tRNA synthetase, vascular endothelial growth factor-mediated stimulation of the Nrp1 receptor has been identified as a therapeutic target. Preclinical advances have been accompanied by the publication of large natural history cohorts and the identification of a sensitive biomarker of disease (muscle MRI) that is able to detect disease progression in CMT1A over 1 year. SUMMARY: Advances in next-generation sequencing technology, cell biology and animal models of CMT are paving the way for rational treatments. The combination of robust natural history data and the identification of sensitive biomarkers mean that we are now entering an exciting therapeutic era in the field of the genetic neuropathies.
Authors: Weiwei He; Hui-Min Zhang; Yeeting E Chong; Min Guo; Alan G Marshall; Xiang-Lei Yang Journal: Proc Natl Acad Sci U S A Date: 2011-07-07 Impact factor: 11.205
Authors: S Rudnik-Schöneborn; D Tölle; J Senderek; K Eggermann; M Elbracht; U Kornak; M von der Hagen; J Kirschner; B Leube; W Müller-Felber; U Schara; K von Au; D Wieczorek; C Bußmann; K Zerres Journal: Clin Genet Date: 2015-04-29 Impact factor: 4.438
Authors: Constantin d'Ydewalle; Jyothsna Krishnan; Driss M Chiheb; Philip Van Damme; Joy Irobi; Alan P Kozikowski; Pieter Vanden Berghe; Vincent Timmerman; Wim Robberecht; Ludo Van Den Bosch Journal: Nat Med Date: 2011-07-24 Impact factor: 53.440
Authors: Obaid M Albulym; Marina L Kennerson; Matthew B Harms; Alexander P Drew; Anna H Siddell; Michaela Auer-Grumbach; Alan Pestronk; Anne Connolly; Robert H Baloh; Stephan Zuchner; Stephen W Reddel; Garth A Nicholson Journal: Ann Neurol Date: 2016-01-13 Impact factor: 10.422
Authors: Sida Shen; Veronick Benoy; Joel A Bergman; Jay H Kalin; Mariana Frojuello; Giulio Vistoli; Wanda Haeck; Ludo Van Den Bosch; Alan P Kozikowski Journal: ACS Chem Neurosci Date: 2015-12-07 Impact factor: 4.418
Authors: Burkhard Gess; Jonathan Baets; Peter De Jonghe; Mary M Reilly; Davide Pareyson; Peter Young Journal: Cochrane Database Syst Rev Date: 2015-12-11
Authors: G Piscosquito; M M Reilly; A Schenone; G M Fabrizi; T Cavallaro; L Santoro; F Manganelli; G Vita; A Quattrone; L Padua; F Gemignani; F Visioli; M Laurà; D Calabrese; R A C Hughes; D Radice; A Solari; D Pareyson Journal: Eur J Neurol Date: 2015-07-31 Impact factor: 6.089
Authors: José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2017-03-31 Impact factor: 4.849
Authors: David Blocquel; Litao Sun; Zaneta Matuszek; Sheng Li; Thomas Weber; Bernhard Kuhle; Grace Kooi; Na Wei; Jonathan Baets; Tao Pan; Paul Schimmel; Xiang-Lei Yang Journal: Proc Natl Acad Sci U S A Date: 2019-09-09 Impact factor: 11.205
Authors: Jaya Punetha; Loren Mackay-Loder; Tamar Harel; Zeynep Coban-Akdemir; Shalini N Jhangiani; Richard A Gibbs; Ian Lee; Deborah Terespolsky; James R Lupski; Jennifer E Posey Journal: Mol Genet Metab Date: 2018-08-24 Impact factor: 4.797